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Sir: Several recent studies clearly
identify the development of hyper-
glycaemia as an important risk
factor in terms of mortality and
morbidity of critically ill patients. In
patients undergoing cardiac surgery,
hyperglycaemia has been associ-
ated with a substantial mortality
risk and delayed extubation [1, 2].
Strong evidence favouring a strat-
egy targeting strict glucose control
(4.5–6.0mmol/l) came from the
landmark prospective, randomized,
controlled study on intensive insulin
therapy in adult surgical critically
ill patients [3]. Recently, the clinical
beneﬁts of this therapy in adults were
largely conﬁrmed in a large, random-
Reference Study group Level of evidence Outcome Key results (95% CI) Comments
[4] Adult ICU patients,
n =2,748; conven-
tional insulin treat-
ment group n =1,388;
intensive insulin treat-
ment (IIT) group
n =1,360
Meta-analysis
(level 1a)
Mortality,
critical illness
polyneuropathy,
renal failure,
hypoglycaemia
Mortality: relative risk
reduction (RRR) 19%
(95% CI: 2–35%);
absolute risk reduc-
tion (ARR): 0.03
(0.004–0.056);
number needed to treat
(NNT): 33 (18–281)
Study limited to adults;
insulin therapy in the con-
ventional treatment group
was initiated when blood
glucose levels exceeded
215mg/dl (12mmol/l),
and adjusted to keep blood
glucose between 180 and
200mg/dl (10–11mmol/l);
in the intensive insulin treat-
ment group, therapy was
initiated when blood glu-
cose was above 110mg/dl
(6mmol/l) and adjusted
to maintain blood glucose
between 80 and 110mg/dl
(4.5–6mmol/l)
Table 1 Overview of relevant papers
ized, controlled trial in a strictly med-
ical adult ICU patient population [4];
however, whether the maintenance
of normoglycaemia in critically ill
children is also beneﬁcial on patient
outcome is undetermined. In an effort
to analyse the presently available ev-
idence related to paediatric critically
ill patients, we performed a structured
critical appraisal of the literature.
In critically ill children (patient)
does insulin therapy in order to main-
tain strict normoglycaemia (inter-
vention) improve survival, or reduce
morbidity (outcome)? We have per-
formed the following search strategy:
Secondary (Cochrane library) and
primary (PubMed) sources were in-
cluded in the search. These databases
were searched for: (“Insulin”[Mesh]
or “Hyperglycemia”[Mesh] or
“Glucose Metabolism Disor-
ders”[Mesh] or “Glucose”[Mesh])
and (“Critical Illness”[Mesh] or
(“Intensive Care”[Mesh] or “Inten-
sive Care Units, Pediatric”[Mesh]))
and systematic [sb] not (“Diabetic
Ketoacidosis”[Mesh] or “Diabetes
Mellitus”[Mesh]). Our search yielded
37 results, ﬁve relevant to the ques-
tion, two related to children. One
of the publications used a pooled
database [4] partly described in
a previous study. [3] One study
was non-observational only. The
three remaining studies are given in
Table 1.
In critically ill adults, it has been
shown that maintenance of strict
normoglycaemia (4.5–6.0mmol/l)
with intensive insulin therapy sub-
stantially prevents morbidity and
reduces mortality [4]. The risk of
hypoglycaemia increases with this
therapy, but it is unclear whether
this is truly harmful in the setting
of adult intensive care. In paediatric
critically ill patients, hypergly-
caemia is prevalent and is associated
with a worse outcome [5, 6]. This
association in itself, however, does
not imply a causal relation. Whereas
in adult studies maintenance of
blood glucose levels between 80
and 110mg/dl (4.5–6.0mmol/l)
has shown to reduce both mortality
and morbidity [4], in the described
paediatric studies higher glucose
levels above 150 mg/dl (8.3mmol/l)
or above 178 mg/dl (10 mmol/l)
have been found to be predict mor-
tality [5, 6]. Uniform criteria to de-
ﬁne hyperglycaemia in critically ill
children have yet to be established
and may differ between age groups.
Moreover, the acute phase of sepsis1549
Reference Study group Level of evidence Outcome Key results (95% CI) Comments
New renal failure:
RRR 42 (18–65), ARR
0.032 (0.014–0.050),
NNT 31 (20–71)
Critical illness poly-
neuropathy: RRR 40
(25–56), ARR 0.063
(0.038–0.088), NNT 16
(11–26)
Hypoglycemia:
RRR −528%
(629 to −427%),
ARR −0.095
(−0.013 to −0.077),
NNH 11 (9–13)
Strict glucose control re-
duced in-hospital mortality
for patients with >3I C U
days but did not lead to
a difference in overall
in-hospital mortality
Mortality or neurological
sequelae in hypogly-
caemic patients: RRR
50% (−237 to 100%),
ARR −0.001 (−0.005
to 0.003), NNH 1,000
(211 to inﬁnite)
[6] Pediatric septic shock
patients (n =57)
Single-center,
prospective observa-
tional cohort study
(level 2c)
Mortality Peak glucose level
in non-survivors
262±110mg/dl
(14.5±6mmol/l) was
higher than in survi-
vors: 167.8±55mg/dl
(9.5±3mmol/l;
p<0.01)
Observational pediatric
study; univariate analysis
identiﬁed three possible
factors that could be as-
sociated with increased
mortality (higher glucose
level, male gender, pediatric
risk of mortality score II
above 10); multivariate
analysis demonstrated that
peak glucose level was the
only independent risk factor
associated with mortality
Best peak glucose level
predicting death was
178mg/dl (10mmol/l),
sensitivity 0.71, speci-
ﬁcity 0.72, relative risk
of death in hypergly-
caemic patients 2.59
(1.37–4.88)
Severity of illness was not
reported; 941 of 1,927 pati-
ents excluded because of
absence of glucose measure-
ment, leading to a possible
selection bias
[5] Pediatric critically ill,
non-diabetic patients
(n =942)
Single-center, retro-
spective observa-
tional cohort study
(level 2c)
Mortality and length
of stay
Peak glucose level above
150mg/dl (8.3mmol/l)
within 10 days of initial
glucose measurement
predicted death with
a sensitivity of 81%
(68–93%), speciﬁcity
51% (48–54%), relative
risk of death 4.13 (1.83–
9.32); length of stay in
hyperglycaemic group
was higher 6.1±9.6
vs. 4.0±6.0 days
(p=0.001)
Table 1 Continued1550
in children may differ signiﬁcantly
from the hyperinsulinaemic hyper-
glycaemia associated with insulin
resistance in adult sepsis. In a recent
study it has been shown that children
in shock due to meningococcal sepsis
showed signs of insufﬁcient insulin
response to hyperglycaemia, whereas
patients without signs of shock were
insulin resistant [7]. In paediatric
critically ill patients, hypoglycaemia
is also prevalent and is related to in-
creased mortality [8]. Hypoglycaemia
was signiﬁcantly more common in
patients receiving intensive insulin
therapy [4]. Insulin therapy in sick
children with high blood glucose
levels, exceeding 178mg/dl
(10 mmol/l), can be advocated, but
based on current evidence, there is
insufﬁcient data to extrapolate to
critically ill children that strict glu-
cose control is beneﬁcial. Currently,
two large registered and ongoing
European randomised controlled
trials on the subject of tight glucose
control in critically ill paediatric
patients are being performed: Control
of Hyperglycaemia in Paediatric
Intensive Care (ISRCTN 61735247,
London, http://www.chip-trial.org.uk)
and Tight Glycemic Control With
Intensive Insulin Treatment in PICU
(NCT00214916, Leuven).
In conclusion, no randomised
controlled studies focusing on strict
glucose control in paediatric patients
were found. In critically ill adults
maintenance of strict normogly-
caemia with intensive insulin therapy
reduces morbidity and mortality
(evidence grade A). In paediatric ill
patients, hyperglycaemia is preva-
lent and levels above 178mg/dl
(10mmol/l) are associated with
increased mortality (grade B).Ill chil-
dren, however, are also susceptible
to hypoglycaemia. Based on current
evidence, insulin therapy aimed at
strict glucose control [blood glucose
levels between 80 and 110mg/dl
(4.5–6mmol/l)] cannot be recom-
mended in paediatric critically ill
patients. Any future change in prac-
tice should be based on evidencefrom
current randomised clinical trials.
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